PR Newswire BiotechOriginal article
The U.S. FDA grants orphan drug designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for treatment of endogenous Cushing's syndrome
RegulatoryapprovedasedebartPositive
AI Analysis
Summary
Lundbeck's investigational anti-ACTH monoclonal antibody asedebart has received Orphan Drug Designation from the U.S. FDA for treatment of endogenous Cushing's syndrome, a rare endocrine disorder.
Outcome Details
Orphan Drug Designation granted by U.S. FDA
Importance:6/10
Sentiment:
0.70
orphan drug designationmonoclonal antibodyendocrine disorderrare disease
Related Companies
Read the original article
Published by PR Newswire Biotech on September 11, 2026 8:21 AM